Pembrolizumab (Keytruda)

Canada’s Drug Agency (CDA-AMC) recommends that Keytruda be reimbursed by public drug plans for the treatment of primary advanced or recurrent endometrial carcinoma in combination with carboplatin and paclitaxel and then continued as monotherapy, if certain conditions are met. Keytruda should only be covered to treat adult patients with newly diagnosed stage III or IVA endometrial cancer with measurable disease, or stage IVB or recurrent endometrial cancer with or without measurable disease, or with metastatic or recurrent endometrial cancer of any histologic subtype except for carcinosarcoma. Keytruda should only be reimbursed in combination with carboplatin and paclitaxel and then continued as monotherapy if it is prescribed by clinicians with expertise in treating endometrial cancer and the cost of Keytruda is reduced.